Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours

Summary

This investigator driven study will examine the safety, efficacy and biological effects of combining pembrolizumab (MK-3475) an antibody targeted against anti-programmed cell death 1 (PD-1), with stereotactic ablative body radiotherapy (SABR) for oligometastatic renal cell carcinoma (RCC). The investigators hypothesise that the safety profile of this combination will be clinically acceptable.

Timeline

Start

2016-10-20

Primary completion

2020-05-22

Completion

2020-05-22

Publications

• Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, A Azad A, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. Eur Urol. 2022 Apr;81(4):364-372. doi: 10.1016/j.eururo.2021.12.006. Epub 2021 Dec 23.
• Pryor D, Bressel M, Lawrentschuk N, Tran B, Mooi J, Lewin J, Azad A, Colyer D, Neha N, Shaw M, Chander S, Neeson P, Moon D, Cuff K, Wood S, Murphy DG, Sandhu S, Loi S, Siva S. A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. Contemp Clin Trials Commun. 2021 Jan 6;21:100703. doi: 10.1016/j.conctc.2021.100703. eCollection 2021 Mar.

Drugs

Indications